Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer
Compared with the standard second-line chemotherapy combined with bevacizumab regimen, second-line therapy that combines chemotherapy with bevacizumab and anti-PD-1 immunotherapy has demonstrated promising efficacy in the treatment of MSS mCRC, while exhibiting a similar safety profile.
Authors
- Shikai Wu (ORCID: https://orcid.org/0000-0002-0317-3148)
- Xuan Jin (ORCID: https://orcid.org/0000-0002-6478-2000)
- Zhigang Shen (ORCID: https://orcid.org/0000-0002-4121-5716)
- Xiaoyan Wang (ORCID: https://orcid.org/0000-0002-0800-5864)
- Xiaoyun Wang (ORCID: https://orcid.org/0000-0002-3052-8979)
- Jiahua Liu (ORCID: https://orcid.org/0000-0002-2121-0491)
- Zhao Gao
Institutions
- Peking University (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3748/wjg.v31.i21.106939
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00